SAVA insider transaction filings
CASSAVA SCIENCES INC — 42 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2025-11-25. Screen SAVA transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for SAVA between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — CASSAVA SCIENCES INC
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-11-25 | 4 | Anderson Robert Eugene Jr — Director | Purchase (P): 8,600 @ $2.90 | EDGAR |
| 2025-11-24 | 4 | Barry Richard — President & CEO, Director | Purchase (P): 150,000 @ $2.76 | EDGAR |
| 2025-11-20 | 4 | Barry Richard — President & CEO, Director | Purchase (P): 73,385 @ $2.75 | EDGAR |
| 2025-10-22 | 4 | Bir Dawn Carter — Director | Grant/award (A): 53,000 (derivative) @ $0 | EDGAR |
| 2025-10-02 | 4 | Cook Robert Christopher — Chief Operating & Legal Office | Purchase (P): 13,725 @ $2.91 | EDGAR |
| 2025-09-23 | 4 | Barry Richard — President & CEO, Director | Purchase (P): 7,172 @ $2.28 | EDGAR |
| 2025-09-22 | 4 | Barry Richard — President & CEO, Director | Purchase (P): 5,400 @ $2.13 · Purchase (P): 185,233 @ $2.24 · Purchase (P): 400 @ $2.25 · Purchase (P): 46,908 @ $2.29 | EDGAR |
| 2025-07-16 | 4 | SCANNON PATRICK J MD PHD — Director | Grant/award (A): 26,500 (derivative) @ $0 | EDGAR |
| 2025-05-27 | 4 | Anderson Robert Eugene Jr — Director | Grant/award (A): 26,500 (derivative) @ $0 | EDGAR |
| 2025-05-27 | 4 | Gravier Pierre — Director | Grant/award (A): 26,500 (derivative) @ $0 | EDGAR |
| 2025-05-27 | 4 | GUSSIN ROBERT Z — Director | Grant/award (A): 26,500 (derivative) @ $0 | EDGAR |
| 2025-05-27 | 4 | Nicaise Claude — Director | Grant/award (A): 26,500 (derivative) @ $0 | EDGAR |
| 2025-05-27 | 4 | O DONNELL MICHAEL J — Director | Grant/award (A): 26,500 (derivative) @ $0 | EDGAR |
| 2025-04-21 | 4 | Schoen Eric — Chief Financial Officer | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2025-04-21 | 4 | Barry Richard — President & CEO, Director | Grant/award (A): 350,000 (derivative) @ $0 | EDGAR |
| 2025-04-21 | 4 | Nassif Freda — Chief Business Officer | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2025-04-21 | 4 | Cook Robert Christopher — Chief Operating & Legal Office | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2024-12-03 | 4 | Kupiec James William — Chief Medical Officer | Sale (S): 4,000 @ $3.87 | EDGAR |
| 2024-12-03 | 4 | Schoen Eric — Chief Financial Officer | Option exercise (M): 50,000 @ $1.18 · Sale (S): 2,000 @ $3.82 · Sale (S): 59,800 @ $3.86 · Option exercise (M): 50,000 (derivative) @ $0 | EDGAR |
| 2024-11-20 | 4 | Landen Jaren — Chief Clinical Dev. Officer | Grant/award (A): 85,000 (derivative) @ $0 | EDGAR |
| 2024-11-20 | 4 | Nassif Freda — Chief Commercial Officer | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2024-10-01 | 4 | Barry Richard — President & CEO, Director | Grant/award (A): 600,000 (derivative) @ $0 | EDGAR |
| 2024-09-09 | 4 | Schoen Eric — Chief Financial Officer | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2024-09-09 | 4 | Cook Robert Christopher — SVP & General Counsel | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2024-09-09 | 4 | Kupiec James William — Chief Medical Officer | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2024-05-22 | 4 | BARBIER REMI — President & CEO, Director | Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-05-22 | 4 | Schoen Eric — Chief Financial Officer | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-05-22 | 4 | Cook Robert Christopher — SVP & General Counsel | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2024-05-22 | 4 | Kupiec James William — Chief Medical Officer | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2024-05-16 | 4 | ROBERTSON SANFORD — Director | Gift (G): 5,000 @ $0 · Gift (G): 5,000 @ $0 | EDGAR |
| 2024-05-13 | 4 | GUSSIN ROBERT Z — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2024-05-13 | 4 | O DONNELL MICHAEL J — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2024-05-13 | 4 | Barry Richard — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2024-05-13 | 4 | ROBERTSON SANFORD — Director | Grant/award (A): 15,000 (derivative) @ $0 | EDGAR |
| 2024-05-13 | 4 | SCANNON PATRICK J MD PHD — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2024-05-13 | 4 | Anderson Robert Eugene Jr — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2024-05-13 | 4 | Gravier Pierre — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2024-05-13 | 4 | Nicaise Claude — Director | Grant/award (A): 10,000 (derivative) @ $0 | EDGAR |
| 2024-04-30 | 4 | ROBERTSON SANFORD — Director | Option exercise (M): 69,000 @ $22 · Grant/award (A): 72,000 (derivative) @ $0 · Grant/award (A): 354,740 (derivative) @ $0 · Option exercise (M): 46,000 (derivative) @ $0 | EDGAR |
| 2024-04-25 | 4 | Barry Richard — Director | Option exercise (M): 176,085 @ $22 · Grant/award (A): 117,390 (derivative) @ $0 · Option exercise (M): 117,390 (derivative) @ $0 | EDGAR |
| 2024-04-22 | 4 | Kupiec James William — Chief Medical Officer | Option exercise (M): 1,500 @ $22 · Grant/award (A): 1,000 (derivative) @ $0 · Option exercise (M): 1,000 (derivative) @ $0 | EDGAR |
| 2024-04-17 | 4 | Schoen Eric — Chief Financial Officer | Option exercise (M): 1,500 @ $22 · Grant/award (A): 7,920 (derivative) @ $0 · Grant/award (A): 800 (derivative) @ $0 · Option exercise (M): 1,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — CASSAVA SCIENCES INC
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-22 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-18 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-07-29 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-15 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-28 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-03-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-10 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-19 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-23 | 8-K | 1.01 — Entry into a Material Definitive Agreement | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=SAVA returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →